A Novel Anticancer Therapy That Simultaneously Targets Aberrant p53 and Notch Activities in Tumors

PLoS ONE

Volumn 7, Issue 10, 2012, Pages

  Yao, Yuting ^a   Wang, Li ^a   Zhang, He ^a,b   Wang, Haibo ^a   Zhao, Xiaoping ^a   Zhang, Yidan ^a   Zhang, Leilei ^a   Fan, Xianqun ^a   Qian, Guanxiang ^a   Hu, Ji Fan ^b   Ge, Shengfang ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; NOTCH RECEPTOR; ONCOLYTIC ADENOVIRUS; PROTEIN MDM2; PROTEIN P53; SMALL INTERFERING RNA; VIRUS DNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GENE THERAPY; CANCER INHIBITION; CONTROLLED STUDY; DNA REPLICATION; DRUG CYTOTOXICITY; DRUG POTENTIATION; FEASIBILITY STUDY; FEMALE; GENE; GENE EXPRESSION; GENETIC TRANSCRIPTION; HEXON GENE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; NUDE MOUSE; ONCOLYTIC VIROTHERAPY; PROTEIN EXPRESSION; PROTEIN TARGETING; RNA TRANSLATION; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT; UTERINE CERVIX CANCER; VIRUS REPLICATION; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; CASPASE 3; CELL PROLIFERATION; COMBINED MODALITY THERAPY; DNA REPLICATION; DNA, VIRAL; ENZYME ACTIVATION; GENE EXPRESSION; GENE KNOCKDOWN TECHNIQUES; HELA CELLS; HUMANS; MALE; MICE; MICE, NUDE; NEOPLASMS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; PROTO-ONCOGENE PROTEINS C-MDM2; RECEPTOR, NOTCH1; RNA INTERFERENCE; RNA, SMALL INTERFERING; TUMOR SUPPRESSOR PROTEIN P53; VIRUS REPLICATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84867370482     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0046627     Document Type: Article

References (49)

1. Bischoff JR, Kirn DH, Williams A, Heise C, Horn S, et al. (1996) An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 274: 373-376.
2. Ries S, Korn WM, (2002) ONYX-015: mechanisms of action and clinical potential of a replication-selective adenovirus. Br J Cancer 86: 5-11.
3. Wiman KG, (2006) Strategies for therapeutic targeting of the p53 pathway in cancer. Cell Death Differ 13: 921-926.
4. Post LE, (2002) Selectively replicating adenoviruses for cancer therapy: an update on clinical development. Curr Opin Investig Drugs 3: 1768-1772.
5. Yu W, Fang H, (2007) Clinical trials with oncolytic adenovirus in China. Curr Cancer Drug Targets 7: 141-148.
6. Kasuya H, Takeda S, Shimoyama S, Shikano T, Nomura N, et al. (2007) Oncolytic virus therapy-foreword. Curr Cancer Drug Targets 7: 123-125.
7. Artavanis-Tsakonas S, Rand MD, Lake RJ, (1999) Notch signaling: cell fate control and signal integration in development. Science 284: 770-776.
8. Parks AL, Klueg KM, Stout JR, Muskavitch MA, (2000) Ligand endocytosis drives receptor dissociation and activation in the Notch pathway. Development 127: 1373-1385.
9. Brou C, Logeat F, Gupta N, Bessia C, LeBail O, et al. (2000) A novel proteolytic cleavage involved in Notch signaling: the role of the disintegrin-metalloprotease TACE. Mol Cell 5: 207-216.
10. Chen J, Kesari S, Rooney C, Strack PR, Shen H, et al. (2010) Inhibition of Notch Signaling Blocks Growth of Glioblastoma Cell Lines and Tumor Neurospheres. Genes Cancer 1: 822-835.
11. Takebe N, Harris PJ, Warren RQ, Ivy SP, (2011) Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways. Nat Rev Clin Oncol 8: 97-106.
12. Pannuti A, Foreman K, Rizzo P, Osipo C, Golde T, et al. (2010) Targeting Notch to target cancer stem cells. Clin Cancer Res 16: 3141-3152.
13. Bolos V, Blanco M, Medina V, Aparicio G, Diaz-Prado S, et al. (2009) Notch signalling in cancer stem cells. Clin Transl Oncol 11: 11-19.
14. Al-Hajj M, Becker MW, Wicha M, Weissman I, Clarke MF, (2004) Therapeutic implications of cancer stem cells. Curr Opin Genet Dev 14: 43-47.
15. Kakarala M, Wicha MS, (2007) Cancer stem cells: implications for cancer treatment and prevention. Cancer J 13: 271-275.
16. Yu H, Zhao X, Huang S, Jian L, Qian G, et al. (2007) Blocking Notch1 signaling by RNA interference can induce growth inhibition in HeLa cells. Int J Gynecol Cancer 17: 511-516.
17. Radtke F, Raj K, (2003) The role of Notch in tumorigenesis: oncogene or tumour suppressor? Nat Rev Cancer 3: 756-767.
18. Garber K, (2007) Notch emerges as new cancer drug target. J Natl Cancer Inst 99: 1284-1285.
19. Weijzen S, Rizzo P, Braid M, Vaishnav R, Jonkheer SM, et al. (2002) Activation of Notch-1 signaling maintains the neoplastic phenotype in human Ras-transformed cells. Nat Med 8: 979-986.
20. Chen Y, De Marco MA, Graziani I, Gazdar AF, Strack PR, et al. (2007) Oxygen concentration determines the biological effects of NOTCH-1 signaling in adenocarcinoma of the lung. Cancer Res 67: 7954-7959.
21. Gao X, Deeb D, Jiang H, Liu Y, Dulchavsky SA, et al. (2007) Synthetic triterpenoids inhibit growth and induce apoptosis in human glioblastoma and neuroblastoma cells through inhibition of prosurvival Akt, NF-kappaB and Notch1 signaling. J Neurooncol 84: 147-157.
22. Palomero T, Lim WK, Odom DT, Sulis ML, Real PJ, et al. (2006) NOTCH1 directly regulates c-MYC and activates a feed-forward-loop transcriptional network promoting leukemic cell growth. Proc Natl Acad Sci U S A 103: 18261-18266.
23. Wang Z, Zhang Y, Li Y, Banerjee S, Liao J, et al. (2006) Down-regulation of Notch-1 contributes to cell growth inhibition and apoptosis in pancreatic cancer cells. Mol Cancer Ther 5: 483-493.
24. Kim HG, Hwang SY, Aaronson SA, Mandinova A, Lee SW, (2011) DDR1 receptor tyrosine kinase promotes prosurvival pathway through Notch1 activation. J Biol Chem 286: 17672-17681.
25. Lefort K, Mandinova A, Ostano P, Kolev V, Calpini V, et al. (2007) Notch1 is a p53 target gene involved in human keratinocyte tumor suppression through negative regulation of ROCK1/2 and MRCKalpha kinases. Genes Dev 21: 562-577.
26. Dotto GP, (2009) Crosstalk of Notch with p53 and p63 in cancer growth control. Nat Rev Cancer 9: 587-595.
27. Roth JA, Swisher SG, Meyn RE, (1999) p53 tumor suppressor gene therapy for cancer. Oncology (Williston Park) 13: 148-154.
28. Alimirah F, Panchanathan R, Davis FJ, Chen J, Choubey D, (2007) Restoration of p53 expression in human cancer cell lines upregulates the expression of Notch1: implications for cancer cell fate determination after genotoxic stress. Neoplasia 9: 427-434.
29. Yugawa T, Handa K, Narisawa-Saito M, Ohno S, Fujita M, et al. (2007) Regulation of Notch1 gene expression by p53 in epithelial cells. Mol Cell Biol 27: 3732-3742.
30. Xiaolin Huang LW, He Zhang, Haibo Wang, Xiaoping Zhao, Guanxiang Qian, Jifan Hu, Shengfang Ge, Xianqun Fan1 (2012) Therapeutic efficacy by targeting correction of Notch1-induced aberrants in uveal tumors. PLoS ONE 7: e44301.
31. Rothmann T, Hengstermann A, Whitaker NJ, Scheffner M, zur Hausen H, (1998) Replication of ONYX-015, a potential anticancer adenovirus, is independent of p53 status in tumor cells. J Virol 72: 9470-9478.
32. Zhang P, Ying L, Xu R, Ge S, Mei W, et al. (2010) Tumor-specific, hypoxia-regulated, WW domain-containing oxidoreductase-expressing adenovirus inhibits human non-small cell lung cancer growth in vivo. Hum Gene Ther 21: 27-39.
33. Kawai H, Wiederschain D, Yuan ZM, (2003) Critical contribution of the MDM2 acidic domain to p53 ubiquitination. Mol Cell Biol 23: 4939-4947.
34. Meulmeester E, Frenk R, Stad R, de Graaf P, Marine JC, et al. (2003) Critical role for a central part of Mdm2 in the ubiquitylation of p53. Mol Cell Biol 23: 4929-4938.
35. Jones SN, Roe AE, Donehower LA, Bradley A, (1995) Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature 378: 206-208.
36. Montes de Oca Luna R, Wagner DS, Lozano G, (1995) Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature 378: 203-206.
37. Carette JE, Graat HC, Schagen FH, Mastenbroek DC, Rots MG, et al. (2007) A conditionally replicating adenovirus with strict selectivity in killing cells expressing epidermal growth factor receptor. Virology 361: 56-67.
38. Yu L, Shimozato O, Li Q, Kawamura K, Ma G, et al. (2007) Adenovirus type 5 substituted with type 11 or 35 fiber structure increases its infectivity to human cells enabling dual gene transfer in CD46-dependent and-independent manners. Anticancer Res 27: 2311-2316.
39. Dix BR, O'Carroll SJ, Myers CJ, Edwards SJ, Braithwaite AW, (2000) Efficient induction of cell death by adenoviruses requires binding of E1B55k and p53. Cancer Res 60: 2666-2672.
40. O'Shea CC, Soria C, Bagus B, McCormick F, (2005) Heat shock phenocopies E1B-55K late functions and selectively sensitizes refractory tumor cells to ONYX-015 oncolytic viral therapy. Cancer Cell 8: 61-74.
41. O'Shea CC, Johnson L, Bagus B, Choi S, Nicholas C, et al. (2004) Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity. Cancer Cell 6: 611-623.
42. Zhang H, Wang H, Zhang J, Qian G, Niu B, et al. (2009) Enhanced therapeutic efficacy by simultaneously targeting two genetic defects in tumors. Mol Ther 17: 57-64.
43. Liang XH, Mungal S, Ayscue A, Meissner JD, Wodnicki P, et al. (1995) Bcl-2 protooncogene expression in cervical carcinoma cell lines containing inactive p53. J Cell Biochem 57: 509-521.
44. Jia R, Jiao Z, Xu X, Wang J, Zhou Y, et al. (2011) Functional significance of B7-H1 expressed by human uveal melanoma cells. Mol Med Report 4: 163-167.
45. Hu JF, Vu TH, Hoffman AR, (1996) Promoter-specific modulation of insulin-like growth factor II genomic imprinting by inhibitors of DNA methylation. J Biol Chem 271: 18253-18262.
46. Hu JF, Vu TH, Hoffman AR, (1997) Genomic deletion of an imprint maintenance element abolishes imprinting of both insulin-like growth factor II and H19. J Biol Chem 272: 20715-20720.
47. Li T, Hu JF, Qiu X, Ling J, Chen H, et al. (2008) CTCF regulates allelic expression of Igf2 by orchestrating a promoter-polycomb repressive complex-2 intrachromosomal loop. Mol Cell Biol 28: 6473-6482.
48. Chen HL, Li T, Qiu XW, Wu J, Ling JQ, et al. (2006) Correction of aberrant imprinting of IGF2 in human tumors by nuclear transfer-induced epigenetic reprogramming. EMBO J 25: 5329-5338.
49. Wang H, Song X, Zhang H, Zhang J, Shen X, et al. (2011) Potentiation of tumor radiotherapy by a radiation-inducible oncolytic and oncoapoptotic adenovirus in cervical cancer xenografts. Int J Cancer 2011: 2613.